Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome

Taş, Faruk; Bilgin, Elif; Karabulut, Senem; Taştekin, Didem; Duranyıldız, Derya

doi:10.3892/mco.2016.759

Cited by 10 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, it is considerably important to investigate the pathogenesis of gastric cancer and identify highly sensitive and specific molecular biomarkers for gastric cancer. Fibronectin is an important ECM protein that ---------------------------------------------------------------------------------------------------------------------------------- has been reported to promote invasiveness of gastric cancer cells, and the serum fibronectin levels of patients with gastric cancer were significantly higher than those in the healthy controls (32,33). FNDC1 contains a major component of the structural domain of fibronectin (10)(11)(12)(13).…”

Section: Discussionmentioning

confidence: 97%

High FNDC1 expression correlates with poor prognosis in gastric cancer

et al. 2018

View full text Add to dashboard Cite

Gastric cancer is a common human cancer worldwide. Fibronectin is an important extracellular matrix protein that has been implicated in many cancers and is known to be associated with proliferation and migration. Fibronectin type III domain containing 1 (FNDC1) contains a major component of the structural domain of fibronectin. The objectives of the present study were to measure FNDC1 expression in gastric cancer tissues and evaluate its value as a potential prognostic marker for gastric cancer. FNDC1 protein expression was analyzed by immunohistochemistry in 98 samples of gastric cancer tissue and 25 adjacent normal tissues. The associations between FNDC1 level and various clinicopathological characteristics were assessed, and the correlation between FNDC1 expression levels and prognosis of patients with gastric cancer was analyzed using a Kaplan-Meier analysis. It was demonstrated that FNDC1 expression in gastric cancer tissues and adjacent tissues was significantly different. FNDC1 expression levels were significantly higher in gastric cancer tissues compared with normal gastric tissues (P<0.001). Among the clinicopathological characteristics evaluated, clinical stage (P<0.001), T classification (P<0.001), N classification (P<0.001) and pathological differentiation (P= 0.044) were significantly associated with high FNDC1 expression. Higher FNDC1 expression level was significantly correlated with poorer survival. The present findings suggest that FNDC1 expression levels may be a promising prognostic biomarker for gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 97%

High FNDC1 expression correlates with poor prognosis in gastric cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The level of plasma FN1 varied in different cancers. Depleted plasma FN1 levels were observed in chronic lymphocytic leukemia and osteomyelosclerosis [23], whereas elevated plasma FN1 levels were found in breast cancer [24] and gastric cancer [25]. The role of FN1 in tumorigenesis and malignant progression has been highly controversial [26].…”

Section: Discussionmentioning

confidence: 99%

Glycoproteomic Analysis Reveals Aberrant Expression of Complement C9 and Fibronectin in the Plasma of Patients with Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a major cause of cancer mortality. Currently used CRC biomarkers provide insufficient sensitivity and specificity; therefore, novel biomarkers are needed to improve the CRC detection. Label-free quantitative proteomics were used to identify and compare glycoproteins, enriched by wheat germ agglutinin, from plasma of CRC patients and age-matched healthy controls. Among 189 identified glycoproteins, the levels of 7 and 15 glycoproteins were significantly altered in the non-metastatic and metastatic CRC groups, respectively. Protein-protein interaction analysis revealed that they were predominantly involved in immune responses, complement pathways, wound healing and coagulation. Of these, the levels of complement C9 (C9) was increased and fibronectin (FN1) was decreased in both CRC states in comparison to those of the healthy controls. Moreover, their levels detected by immunoblotting were validated in another independent cohort and the results were consistent with in the study cohort. Combination of CEA, a commercial CRC biomarker, with C9 and FN1 showed better diagnostic performance. Interestingly, predominant glycoforms associated with acetylneuraminic acid were obviously detected in alpha-2 macroglobulin, haptoglobin, alpha-1-acid glycoprotein 1, and complement C4-A of CRC patient groups. This glycoproteomic approach provides invaluable information of plasma proteome profiles of CRC patients and identification of CRC biomarker candidates.

show abstract

“…Fibronectin binds cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. The enhanced plasma level of fibronectin may be used as a diagnostic marker in patients with GC [179]. FN levels were significantly elevated at all stages of BC and returned to normal after tumor removal [180].…”

Section: Fibronectin (Finc_human)mentioning

confidence: 98%

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Naryzhny¹,

Ронжина²,

Zorina³

et al. 2022

Preprint

View full text Add to dashboard Cite

Cancer is a complex systemic disease that changes the entire proteome. The analysis of this transformation makes it possible to determine tumor markers, that is, the most characteristic biomacromolecules produced by tumor cells. Here, the question of finding ideal tumor markers, which should be sensitive, specific, and reliable, is an acute issue. Unfortunately, none of the tumor markers, even those used in the clinic, has all these characteristics. Despite this, many tumor markers have demonstrated excellent clinical relevance for monitoring the effectiveness of different treatments for cancer patients. The use of markers also aids in the early detection of cancer recurrence and prognosis. Therefore, the situation in this area can be improved in two ways – by attempting to find an ideal single tumor marker or generating panels of different markers. In both cases, proteomics certainly plays a major role. Human plasma is one of the most popular samples as it is commonly collected in the clinic and provides noninvasive, rapid analysis for any type of disease including cancer. Many efforts have been applied in searching for “ideal” tumor markers digging very deep plasma proteome. There is a line of evidence that the most abundant, so-called “classical plasma proteins”, may be used to generate a tumor biomarker profile. To be comprehensive these profiles should have information not only about protein levels but proteoform distribution for each protein. Initially, the profile of these proteins in norm should be generated. Here, we present data about these profiles generated by two-dimensional electrophoresis with the following mass-spectrometry and immunodetection.

show abstract

Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome

Cited by 10 publications

References 9 publications

High FNDC1 expression correlates with poor prognosis in gastric cancer

High FNDC1 expression correlates with poor prognosis in gastric cancer

Glycoproteomic Analysis Reveals Aberrant Expression of Complement C9 and Fibronectin in the Plasma of Patients with Colorectal Cancer

Construction of 2DE-Patterns of Plasma Proteins: Aspect of Potential Tumor Markers

Contact Info

Product

Resources

About